Show simple item record

dc.contributor.authorRoy, Alvaro
dc.contributor.authorTomé, Irene
dc.contributor.authorRomero, Beatriz
dc.contributor.authorLorente-Leal, Víctor
dc.contributor.authorInfantes-Lorenzo, José Antonio
dc.contributor.authorDominguez-Rodriguez, Mercedes 
dc.contributor.authorMartín, Carlos
dc.contributor.authorAguilo, Nacho
dc.contributor.authorPuentes, Eugenia
dc.contributor.authorRodríguez, Esteban
dc.contributor.authorJuan, Lucía de
dc.contributor.authorRisalde, María A
dc.contributor.authorGortázar, Christian
dc.contributor.authorDomínguez, Lucas
dc.contributor.authorBezos, Javier
dc.identifier.citationVet Res. 2019 Oct 15;50(1):82.es_ES
dc.description.abstractEffective vaccines against tuberculosis (TB) are needed in order to prevent TB transmission in human and animal populations. Evaluation of TB vaccines may be facilitated by using reliable animal models that mimic host pathophysiology and natural transmission of the disease as closely as possible. In this study, we evaluated the immunogenicity and efficacy of two attenuated vaccines, BCG and MTBVAC, after each was given to 17 goats (2 months old) and then exposed for 9 months to goats infected with M. caprae. In general, MTBVAC-vaccinated goats showed higher interferon-gamma release than BCG vaccinated goats in response to bovine protein purified derivative and ESAT-6/CFP-10 antigens and the response was significantly higher than that observed in the control group until challenge. All animals showed lesions consistent with TB at the end of the study. Goats that received either vaccine showed significantly lower scores for pulmonary lymph nodes and total lesions than unvaccinated controls. Both MTBVAC and BCG vaccines proved to be immunogenic and effective in reducing severity of TB pathology caused by M. caprae. Our model system of natural TB transmission may be useful for evaluating and optimizing vaccines.es_ES
dc.description.sponsorshipThis work was funded by the Spanish Ministry of Economy, Industry and Competitiveness (MINECO, Grant Number: IPT-2012-0327-090000). AR is the recipient of an Industrial Doctorate contract (DI15-08110) funded by the MINECO and the European Social Fund. JB is the recipient of a Juan de la Cierva Incorporation Research contract (IJCI-2015-24805) funded by MINECO.es_ES
dc.publisherBioMed Central (BMC) es_ES
dc.titleEvaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosises_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderMinisterio de Economía, Industria y Competitividad (España) 
dc.identifier.journalVeterinary researches_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional